| Dr Steven James Vandenberg, MD | |
|
1520 N Meade St, Appleton, WI 54911-3762 | |
| (920) 734-7181 | |
| (920) 734-0621 |
| Full Name | Dr Steven James Vandenberg |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 31 Years |
| Location | 1520 N Meade St, Appleton, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295727345 | NPI | - | NPPES |
| 32440900 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 35659 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Thedacare Regional Medical Center - Appleton Inc | Appleton, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ear Nose And Throat Surgical Associates Sc | 5991803702 | 7 |
News Archive
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
When prostate cancer spreads, it most often spreads to bone. And while the 5-year survival rate for prostate cancer that has not spread is nearly 100 percent, once the disease reaches bone, the 5-year survival rate is only 29 percent.
The American Hospital Association says the audit program is preventing hospitals from being reimbursed for care they provide.
TaiGen Biotechnology Company, Limited today announced that they have signed an exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn) in the Russian Federation, Turkey and other members of the Commonwealth Independent States.
› Verified 1 days ago
| Entity Name | Ear Nose & Throat Surgical Associates Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629094214 PECOS PAC ID: 5991803702 Enrollment ID: O20070601000252 |
News Archive
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
When prostate cancer spreads, it most often spreads to bone. And while the 5-year survival rate for prostate cancer that has not spread is nearly 100 percent, once the disease reaches bone, the 5-year survival rate is only 29 percent.
The American Hospital Association says the audit program is preventing hospitals from being reimbursed for care they provide.
TaiGen Biotechnology Company, Limited today announced that they have signed an exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn) in the Russian Federation, Turkey and other members of the Commonwealth Independent States.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Steven James Vandenberg, MD 1520 N Meade St, Appleton, WI 54911-3762 Ph: (920) 991-0188 | Dr Steven James Vandenberg, MD 1520 N Meade St, Appleton, WI 54911-3762 Ph: (920) 734-7181 |
News Archive
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
When prostate cancer spreads, it most often spreads to bone. And while the 5-year survival rate for prostate cancer that has not spread is nearly 100 percent, once the disease reaches bone, the 5-year survival rate is only 29 percent.
The American Hospital Association says the audit program is preventing hospitals from being reimbursed for care they provide.
TaiGen Biotechnology Company, Limited today announced that they have signed an exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn) in the Russian Federation, Turkey and other members of the Commonwealth Independent States.
› Verified 1 days ago
Dr. Todd Andrew Meyer, D.O. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1501 S Madison St, Appleton, WI 54915 Phone: 920-730-4443 | |
Dr. Mitchell Francis Kwaterski, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 1520 N Meade St, Appleton, WI 54911 Phone: 920-734-7181 Fax: 920-734-0621 | |
Dr. Matthew Edward Bettag, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1520 N Meade St, Appleton, WI 54911 Phone: 920-734-7181 Fax: 920-734-0621 | |
Dr. Michael James Mcavoy, D. O. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1520 N Meade St, Appleton, WI 54911 Phone: 920-734-7181 Fax: 920-734-0621 | |
Gregory J Swanson, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1501 S Madison St, Appleton, WI 54915 Phone: 920-730-4443 | |
Dr. Ryan Timothy Funk, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 247 S Nicolet Rd, Appleton, WI 54914 Phone: 888-938-3838 Fax: 888-919-1083 |